Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines.

Recommendations for the Design and Use of Standard Virus Panels To Assess Neutralizing Antibody Responses Elicited by Candidate Human Immunodeficiency Virus Type 1 Vaccines John R. Mascola,* Patricia D’Souza, Peter Gilbert, Beatrice H. Hahn, Nancy L. Haigwood, Lynn Morris, Christos J. Petropoulos, Victoria R. Polonis, Marcella Sarzotti, and David C. Montefiori Vaccine Research Center and Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892; Statistical Center for HIV/AIDS Research and Prevention, University of Washington, Seattle, Washington 98109; Departments of Medicine and Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 35294; Seattle Biomedical Research Institute, Seattle, Washington 98109; National Institute for Communicable Diseases, Johannesburg, South Africa; ViroLogic, Inc., South San Francisco, California 94080; Henry M. Jackson Foundation, Rockville, Maryland 20850; and Departments of Immunology and Surgery, Duke University Medical Center, Durham, North Carolina 27710